Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asenapine fixed-dose 6-week trial in adults with schizophrenia
2010-018407-28Phase 3Completed
- Sponsor
- Schering-Plough Research Institute
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asenapine in schizophrenia (5 arms), sponsored by Schering-Plough Research Institute. Primary endpoint: Change from baseline to Day 42 in PANSS total score. Started Apr 2013; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-018407-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018407-28.